Our Health Library information does not replace the advice of a doctor. Please be advised that this information is made available to assist our patients to learn more about their health. Our providers may not see and/or treat all topics found herein.

Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Injection

(as par' a jin ase) (er win' ee a) (kri san' the mee)

Brand Name(s): Rylaze®

WHY is this medicine prescribed?

Asparaginase erwinia chrysanthemi (recombinant)-rywn injection is used with other chemotherapy medications to treat acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells) and to treat a type of non-Hodgkins lymphoma (NHL: cancer that begins in a type of white blood cell that normally fights infection) in adults and children 1 month of age and older. It is used in people who have had some types of allergic reactions to medications similar to asparaginase erwinia chrysanthemi (recombinant)-rywn such as asparaginase (Elspar). Asparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that interferes with natural substances necessary for cancer cell growth. It works by killing or stopping the growth of cancer cells.

Are there OTHER USES for this medicine?

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

HOW should this medicine be used?

Asparaginase erwinia chrysanthemi (recombinant)-rywn comes as a solution (liquid) to be given intramuscularly (injected into a muscle) by a doctor or nurse in a medical facility. It is usually given every 48 hours. It may also be given three times a week, every Monday morning, every Wednesday, morning, and every Friday afternoon. The length of treatment depends on how you respond to the medication.

Your doctor may need to delay your treatment or stop your treatment if you experience certain side effects. It is important for you to tell your doctor how you are feeling during your treatment with asparaginase erwinia chrysanthemi (recombinant)-rywn injection.

Asparaginase erwinia chrysanthemi (recombinant)-rywn injection may cause serious allergic reactions. You will be given medications 30 to 60 minutes before your injection to help prevent reactions to asparaginase erwinia chrysanthemi (recombinant)-rywn. A doctor or nurse will watch you closely while you are receiving asparaginase erwinia chrysanthemi (recombinant)-rywn injection. Tell your doctor or nurse immediately if you experience any of the following symptoms: rash; hives; swelling of face, lips, eyes, arms, or legs; or shortness of breath or difficulty breathing.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

What SPECIAL PRECAUTIONS should I follow?

Before receiving asparaginase erwinia chrysanthemi (recombinant)-rywn,

  • tell your doctor and pharmacist if you are allergic to asparaginase erwinia chrysanthemi (recombinant)-rywn, any other medications, or any of the ingredients in asparaginase erwinia chrysanthemi (recombinant)-rywn. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had pancreatitis (swelling of the pancreas), blood clots, or severe bleeding, especially if these happened during treatment with asparaginase (Elspar). Your doctor probably will not want you to receive asparaginase erwinia chrysanthemi (recombinant)-rywn.

  • tell your doctor if you have or have ever had diabetes or any other medical conditions.

  • tell your doctor if you are pregnant or plan to become pregnant. You will need to take a pregnancy test before you start treatment and use a non-hormonal birth control (device that blocks sperm from entering the uterus such as a condom or a diaphragm) during your treatment and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you become pregnant while receiving asparaginase erwinia chrysanthemi (recombinant)-rywn, call your doctor immediately. Asparaginase erwinia chrysanthemi (recombinant)-rywn may harm the fetus.

  • tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving asparaginase erwinia chrysanthemi (recombinant)-rywn and for 1 week after the final dose.

What SPECIAL DIETARY instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

What SIDE EFFECTS can this medicine cause?

Asparaginase erwinia chrysanthemi (recombinant)-rywn may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • nausea
  • diarrhea
  • constipation
  • muscle or bone pain
  • headache
  • tiredness
  • loss of appetite
  • difficulty falling asleep or staying asleep
  • sores on the lips, mouth, or throat
  • numbness or tingling in your hands, feet, arms, or legs

Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

  • swelling of face, lips, eyes, arms, or legs
  • hives
  • itching
  • rash or redness
  • shortness of breath or difficulty breathing
  • yellowing of skin or eyes, pain in upper right part of stomach, dark-colored urine, or loss of appetite
  • unusual bleeding or bruising
  • nose bleeding
  • blood in urine
  • blurred vision, headache, arm or leg swelling, shortness of breath, and chest pain
  • fever, chills, cough, or other signs of infection
  • rapid or increased heart rate
  • ongoing pain that begins in the stomach area, but may spread to the back; fever; weight loss; or nausea and vomiting

Asparaginase erwinia chrysanthemi (recombinant)-rywn may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What should I do in case of OVERDOSE?

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

What OTHER INFORMATION should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to asparaginase erwinia chrysanthemi (recombinant)-rywn.

Ask your pharmacist any questions you have about asparaginase erwinia chrysanthemi (recombinant)-rywn.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Dear patient

I am excited to announce that I will be relocating my practice to Houston Methodist DeBakey Cardiology Associates. Starting November 4, 2024, my new address will be:

Houston Methodist DeBakey Cardiology Associates
6550 Fannin St.
Smith Tower, Suite 1901
Houston, TX 77030

Please note that my phone number and fax number will also change to the following:
24-Hour Telephone: 713-441-1100
Fax: 713-790-2643
Clinical Support Telephone (M-F, 8-5): 713-441-3515

I am excited about caring for you in my new office and hope you will make the transition with me. I will also continue to refill your medications as I have in the past. To assist, please provide your pharmacy with my new contact information.

Please consider checking your prescription refills to verify that you have enough medication on hand to last you until your next visit. Please note that your medical records will remain at my former office until you authorize their transfer. If you choose for me to continue providing your medical care, please complete and sign the enclosed “Authorization for Release of Medical Records” form and fax it to 713-790-2643. Once we receive your authorization, we will be happy to process the request for you.

Thank you for entrusting me with your medical care. My new team and I are dedicated to making this transition as seamless as possible. For help scheduling an appointment and transitioning your care, please call my new office number above.

I look forward to continuing your care at my new location.

Sincerely,
Gopi A. Shah, MD

Dear patient

Dr. Albert Raizner, Dr. Michael Raizner, and Dr. Mohamed El-Beheary are excited to announce that our practice, Interventional Cardiology Associates, will merge with Houston Cardiovascular Associates on November 1, 2024.

Our new offices are similarly located in Houston, near the Texas Medical Center and in Sugar Land. Our in-hospital care will continue at Houston Methodist Hospital in the Texas Medical Center and Houston Methodist Sugar Land Hospital. Importantly, our new offices expand our services with state-of-the-art equipment and amenities. Our core values will always be, as they began over 40 years ago when Dr. Albert Raizner founded ICA:

Integrity – Compassion – Accountability

Our new address and contact information are:

Your medical records are confidential and remain available at our new locations. We consider it a privilege to serve as your cardiologists and look forward to your continuing with us. However, should you desire to transfer to another physician, you may request a copy of your records by contacting us at our new addresses and phone numbers listed above.

We thank you for your trust and loyalty. As always, we will continue to be here to take care of you. Please do not hesitate to contact us if you have any questions or concerns.

Sincerely,

Dr. Albert Raizner,
Dr. Michael Raizner,
Dr. Mohamed El-Beheary